Janus 激酶抑制剂治疗炎症性肠病：来自 I 期和 II 期临床试验的进展。
Janus kinase inhibitors for the treatment of inflammatory bowel diseases: developments from phase I and phase II clinical trials.
机构信息
a Department of Biomedical Sciences , Humanitas University , Milan , Italy.
b IBD Center, Department of Gastroenterology , Humanitas Clinical and Research Institute , Milan , Italy.
出版信息
Expert Opin Investig Drugs. 2018 Jul;27(7):595-599. doi: 10.1080/13543784.2018.1492547. Epub 2018 Jul 6.
INTRODUCTION
A new pharmacological class, Janus kinases (JAK) inhibitors, has been shown to be effective and safe for the treatment of inflammatory bowel diseases (IBDs). The aim of this review is to provide an overview of the JAK inhibitors currently under investigation in phase I and II clinical trials for patients with Crohn's disease and ulcerative colitis and the possible future perspectives for the treatment of IBD patients with this class of drugs.
AREAS COVERED
This review describes the JAK-STAT pathway and analyzes the efficacy and safety of new small molecules such as filgotinib, upadacitinib, TD-1473, peficitinib, and Pf-06651600/Pf-06700841, showing data from phase I and II trials.
EXPERT OPINION
JAK inhibitors, if approved by the regulatory authorities, could represent a novel and intriguing drug class. In the next years, the approach to patients with IBD will become increasingly personalized.
简介
Janus 激酶（JAK）抑制剂作为一种新的药理学类别，已被证明对治疗炎症性肠病（IBD）有效且安全。本综述的目的是概述目前正在进行的 I 期和 II 期临床试验中用于治疗克罗恩病和溃疡性结肠炎患者的 JAK 抑制剂，以及此类药物治疗 IBD 患者的可能未来前景。
涵盖领域
本综述描述了 JAK-STAT 通路，并分析了新型小分子如 filgotinib、upadacitinib、TD-1473、peficitinib 和 Pf-06651600/Pf-06700841 的疗效和安全性，展示了来自 I 期和 II 期试验的数据。
专家意见
如果获得监管机构的批准，JAK 抑制剂可能代表一种新颖且有趣的药物类别。在未来几年，IBD 患者的治疗方法将变得越来越个性化。
Zotero 插件